Panacea Global, Inc. (PGI) is a biotechnology company focusing on developing and commercializing products for the early detection, diagnosis and monitoring the recurrence of cancer. Panacea’s novel product is a blood test that can measure the blood level of Human Aspartyl (Asparaginyl) B-Hydroxylase (HAAH). HAAH, a novel cancer biomarker, is an enzyme which is over expressed in cancer cells and is the foundation of our breakthrough technology.

HAAH Blood test PGI offers patients with accurate, reliable and fast HAAH detection test PGI offers patients with non-invasive, highly accurate, reliable, fast and cost-effective HAAH detection tests, which can be used for early diagnosis, remission and recurrence of cancer following the treatment.